Home » Newsletters » BioWorld Science

BioWorld Science

May 21, 1999

View Archived Issues

Cerep and Pfizer establish drug discovery partnership

NIH grant awarded to Ixion to explore novel kidney stone therapy

Digene enters marketing alliance with Abbott

Ilex Oncology: Q1 1999 highlights

Phase Ib commences, phase Ia completed for Cerus's pathogen inactivation system

Xoma: Q1 1999 highlights

Centocor's Remicade studied as maintenance therapy for Crohn's disease

CTX granted to Alizyme for gastrointestinal therapy

Lundbeck licenses European rights to antiparkinsonian compound

FTY-720 featured at two transplant meetings this week

Protein Design Labs and Progenics enter humanization agreement for anti-CCR5 antibody

Ares-Serono and Axonyx to collaborate on treatment for neurodegenerative diseases

Avax enters research agreement with University of Tokyo for breast cancer vaccine

News from DDW: excellent efficacy reported with prucalopride for treatment of constipation

Quinoline-containing alpha-ketoamides as inhibitors of cysteine and serine proteases

Merck discloses potent, selective and orally active PDE4 inhibitors

Abbott reports preparation and activity of novel erythromycin ketolides

Different crystalline forms of cipamfylline studied at SB

Research at Kyorin leads to AMPA receptor antagonists with nanomolar affinity

Ditropan XL compares favorably to immediate-release oxybutynin in phase III trial

Trial results presented at ACOG meeting support efficacy and safety of imiquimod 5% cream

Once-monthly contraceptive not associated with any unintended pregnancies in large trial

News from ASCO: phase I trial of PNU-214565 dose escalation tied to baseline anti-SEA antibodies

CCK-B/gastrin antagonist CR-2945 prevents colorectal cancer in mice

PDT with temoporfin is a promising treatment for GI tumors

Generex releases additional clinical trial data on Oralin

Texas Biotechnology: Q1 1999 highlights

Positive findings from phase I trial of LY-353381 reported at ASCO meeting, lead to phase II study

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...